3 European Stocks Estimated To Be Trading At Discounts Up To 49.8%
The European stock market has recently shown resilience with the STOXX Europe 600 Index gaining 1.70%, bolstered by robust earnings and a firmer risk appetite despite ongoing geopolitical volatility. In such an environment, identifying undervalued stocks can be particularly appealing, as they may offer potential opportunities for investors looking to capitalize on discrepancies between market prices and intrinsic values.
Top 10 Undervalued Stocks Based On Cash Flows In Europe
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| ZEAL Network (XTRA:TIMA) | €43.40 | €86.56 | 49.9% |
| TGS (OB:TGS) | NOK132.70 | NOK262.35 | 49.4% |
| Stille (OM:STIL) | SEK234.00 | SEK462.59 | 49.4% |
| Micro Systemation (OM:MSAB B) | SEK89.00 | SEK177.36 | 49.8% |
| Metriks AI. Società Benefit (BIT:MTK) | €3.44 | €6.78 | 49.3% |
| JOST Werke (XTRA:JST) | €56.60 | €112.29 | 49.6% |
| Fine Foods & Pharmaceuticals N.T.M (BIT:FF) | €8.22 | €16.29 | 49.6% |
| Elekta (OM:EKTA B) | SEK50.40 | SEK100.30 | 49.8% |
| Cicor Technologies (SWX:CICN) | CHF127.60 | CHF250.28 | 49% |
| Casta Diva Group (BIT:CDG) | €3.05 | €6.09 | 49.9% |
Below we spotlight a couple of our favorites from our exclusive screener.
ALK-Abelló (CPSE:ALK B)
Overview: ALK-Abelló A/S is an allergy solutions company that develops treatments for respiratory allergies, anaphylaxis, and food allergies across various regions including the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, and China with a market cap of DKK49.63 billion.
Operations: The company's revenue is primarily derived from its allergy treatment segment, which generated DKK6.56 billion.
Estimated Discount To Fair Value: 27.4%
ALK-Abelló is trading at DKK224, significantly below its estimated future cash flow value of DKK308.64, suggesting undervaluation. Its earnings are projected to grow 14.6% annually, outpacing the Danish market's 8.2%. Recent approvals for neffy in Canada and EURneffy in the UK bolster its product lineup, potentially enhancing revenue growth forecasted at 12.1% per year—above the market average of 3.9%. Analysts expect a stock price increase of 33.4%.
- According our earnings growth report, there's an indication that ALK-Abelló might be ready to expand.
- Click to explore a detailed breakdown of our findings in ALK-Abelló's balance sheet health report.
Universal Music Group (ENXTAM:UMG)
Overview: Universal Music Group N.V. operates as a global music company and has a market cap of approximately €28.19 billion.
Operations: The company's revenue segments include Recorded Music at €9.76 billion and Music Publishing at €2.30 billion.
Estimated Discount To Fair Value: 43.9%
Universal Music Group is trading at €15.57, well below its estimated future cash flow value of €27.72, highlighting potential undervaluation. Although profit margins have decreased from 21.4% to 2.5%, earnings are forecasted to grow significantly at 27.22% annually over the next three years, surpassing the Dutch market's growth rate of 17.2%. Recent share buybacks totaling €499 million and a new strategic licensing agreement with TikTok may strengthen financial positioning despite high debt levels and volatile share prices.
- Our expertly prepared growth report on Universal Music Group implies its future financial outlook may be stronger than recent results.
- Navigate through the intricacies of Universal Music Group with our comprehensive financial health report here.
Elekta (OM:EKTA B)
Overview: Elekta AB (publ) is a medical technology company that offers clinical solutions for treating cancer and brain disorders across various regions including the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with a market cap of approximately SEK19.26 billion.
Operations: The company's revenue is segmented as follows: SEK5.55 billion from the Asia Pacific, SEK4.46 billion from the Americas, and SEK6.71 billion from Europe, the Middle East, and Africa (EMEA).
Estimated Discount To Fair Value: 49.8%
Elekta is trading at SEK50.4, significantly below its estimated future cash flow value of SEK100.3, suggesting it is undervalued based on cash flows. Despite high debt levels and a recent net loss of SEK519 million for the fiscal year 2025/26, Elekta's revenue growth forecast of 4.2% annually surpasses the Swedish market average decline of 1.5%. The company anticipates improved EBIT margins in fiscal year 2026/27, indicating potential financial recovery.
- Our earnings growth report unveils the potential for significant increases in Elekta's future results.
- Click here and access our complete balance sheet health report to understand the dynamics of Elekta.
Taking Advantage
- Click this link to deep-dive into the 215 companies within our Undervalued European Stocks Based On Cash Flows screener.
- Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
- Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.
Want To Explore Some Alternatives?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com